ArticleAnnals of the rheumatic diseases2022
Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study.
Article in Annals of the rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03026504 (Baricitinib in Relapsing Giant Cell Arteritis), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Baricitinib in Relapsing Giant Cell Arteritis (GCA): A Phase II, Single-institution, Open-label Pilot Study
Who cites it
32 citing papers in PubMed, 82 citations in OpenAlex.
- Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial.Rheumatology (Oxford, England) · 2025Trial
- Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden.Frontiers in immunology · 2023Trial
- Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.Nature reviews. Rheumatology · 2026Review
- Large vessel vasculitis reframed: integrating conceptual shifts and evidence into practice for Takayasu arteritis and giant cell arteritis.Journal of rheumatic diseases · 2026Review
- Review
- Janus Kinase inhibitors in the treatment of large vessel vasculitis: a systematic review and meta-analysis.Open medicine (Warsaw, Poland) · 2026Article
- The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted Therapy.Biomolecules · 2025Review
- A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis.Annals of the rheumatic diseases · 2025Article
- Review
- Illness Burden and Unmet Patient Needs in Giant Cell Arteritis: Current State and Future Prospects.Open access rheumatology : research and reviews · 2025Review
- [News on the treatment of large vessel vasculitis].Zeitschrift fur Rheumatologie · 2024Review
- Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies.RMD open · 2024Article
- Vascular disease persistence in giant cell arteritis: are stromal cells neglected?Annals of the rheumatic diseases · 2024Review
- Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.Arthritis research & therapy · 2024Review
- Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre.RMD open · 2024Article
- Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice.Cells · 2024Review
- Novel and potential future therapeutic options in systemic autoimmune diseases.Frontiers in immunology · 2024Review
- Polymyalgia rheumatica: An update (Review).Experimental and therapeutic medicine · 2023Article
- Advances and challenges in management of large vessel vasculitis.Rheumatology and immunology research · 2023Article
- Immunology of Giant Cell Arteritis.Circulation research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
background/purposePreclinical vascular inflammation models have demonstrated effective suppression of arterial wall lesional T cells through inhibition of Janus kinase 3 and JAK1. However, JAK inhibition in patients with giant cell arteritis (GCA) has not been prospectively investigated.
methodsWe performed a prospective, open-label, pilot study of baricitinib (4 mg/day) with a tiered glucocorticoid (GC) entry and accelerated taper in patients with relapsing GCA.
results15 patients were enrolled (11, 73% female) with a mean age at entry of 72.4 (SD 7.2) years, median duration of GCA of 9 (IQR 7-21) months and median of 1 (1-2) prior relapse. Four (27%) patients entered the study on prednisone 30 mg/day, 6 (40%) at 20 mg/day and 5 (33%) at 10 mg/day. Fourteen patients completed 52 weeks of baricitinib. At week 52, 14/15 (93%) patients had ≥1 adverse event (AE) with the most frequent events, including infection not requiring antibiotics (n=8), infection requiring antibiotics (n=5), nausea (n=6), leg swelling (n=2), fatigue (n=2) and diarrhoea (n=1). One subject required baricitinib discontinuation due to AE. One serious adverse event was recorded. Only 1 of 14 (7%) patients relapsed during the study. The remaining 13 patients achieved steroid discontinuation and remained in disease remission during the 52-week study duration.
conclusionIn this proof-of-concept study, baricitinib at 4 mg/day was well tolerated and discontinuation of GC was allowed in most patients with relapsing GCA. Larger randomised clinical trials are needed to determine the utility of JAK inhibition in GCA. TRIAL REGISTRATION NUMBER: NCT03026504.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.